Using edaravone to treat optic neuritis
Edaravone in the Treatment of Optic Neuritis
This study is testing if edaravone can help improve vision in Chinese adults who have recently experienced optic neuritis and have a specific antibody in their system.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Guangxi Medical University Academic / other |
| Locations | 1 site (Nanning) |
| Trial ID | NCT05540262 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of edaravone on patients with optic neuritis who test positive for aquaporin-4 antibodies. The study aims to determine if edaravone can promote remyelination and protect axons, potentially improving visual outcomes. Eligible participants are Chinese adults experiencing their first episode of optic neuritis within the last 30 days. The trial will assess the efficacy of edaravone as a treatment option for this condition.
Who should consider this trial
Good fit: Ideal candidates are Chinese patients aged 18 and older with a first episode of anti-aquaporin-4 antibody-positive optic neuritis.
Not a fit: Patients with severe myopia or those with conditions affecting visual assessment may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve visual outcomes for patients with optic neuritis.
How similar studies have performed: While edaravone has shown promise in animal models, this specific application in optic neuritis is novel and has not been extensively tested in human subjects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: 1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Where this trial is running
Nanning
- Yi Du — Nanning, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.